Gilead Sciences Plans Western China Ops Center in Chengdu

Gilead Sciences
Published on: Jul 12, 2019
Author: Amy Liu

Gilead Sciences signed a strategic cooperation agreement with Chengdu Hi-tech Zone to develop a Western China Operation Center at the Chengdu park. Gilead is known for developing drugs for difficult-to-treat infections, especially HIV/AIDS and hepatitis C. Its first China approval came in 2017 for the hepatitis C treatment Solvadi. In China, Gilead opened a Shanghai commercial office in 2016. Currently, Gilead is conducting clinical trials of sofosbuvir/velpatasvir, the company’s single-tablet treatment for HCV, at sites across China. Source: China Biotoday

Biotechnology Healthcare Services Life Science Medical Device Pharmaceutical